

## General

### Title

Lipid management in adults: percentage of patients on a lipid lowering medication who have a fasting lipid panel every 3 to 12 months.

### Source(s)

Institute for Clinical Systems Improvement (ICSI). Lipid management in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2009 Oct. 72 p. [109 references]

## Measure Domain

### Primary Measure Domain

#### Process

The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the [Measure Validity](#) page.

### Secondary Measure Domain

Does not apply to this measure

## Brief Abstract

### Description

This measure is used to assess the percentage of patients on a lipid-lowering medication who have a fasting lipid panel every 3 to 12 months.

### Rationale

The priority aim addressed by this measure is to improve the percentage of patients on lipid-lowering medication who receive regular follow-up care for lipid disorder.

### Primary Clinical Component

Dyslipidemia; lipid-lowering medication (bile acid sequestrant [BAS], fibric acids, niacin, statins); fasting lipid panel (total cholesterol, high-density lipoprotein [HDL]-cholesterol, triglycerides, and calculated low-density lipoprotein [LDL]-cholesterol)

## Denominator Description

Total number of patients age 20 to 75 years old who are dyslipidemic and on lipid-lowering medication whose records are reviewed (see the related "Denominator Inclusions/Exclusions" field in the Complete Summary)

## Numerator Description

Number of patients on lipid-lowering medication who have had a fasting lipid panel in the past 3 to 12 months (see the related "Numerator Inclusions/Exclusions" field in the Complete Summary)

## Evidence Supporting the Measure

### Evidence Supporting the Criterion of Quality

A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence

## Evidence Supporting Need for the Measure

### Need for the Measure

Unspecified

## State of Use of the Measure

### State of Use

Current routine use

### Current Use

Internal quality improvement

## Application of Measure in its Current Use

### Care Setting

Physician Group Practices/Clinics

### Professionals Responsible for Health Care

Physicians

## Lowest Level of Health Care Delivery Addressed

Group Clinical Practices

## Target Population Age

Age 20 to 75 years

## Target Population Gender

Either male or female

## Stratification by Vulnerable Populations

Unspecified

# Characteristics of the Primary Clinical Component

## Incidence/Prevalence

Unspecified

## Association with Vulnerable Populations

Unspecified

## Burden of Illness

Unspecified

## Utilization

Unspecified

## Costs

Unspecified

# Institute of Medicine (IOM) Healthcare Quality Report Categories

## IOM Care Need

## IOM Domain

Effectiveness

## Data Collection for the Measure

### Case Finding

Users of care only

### Description of Case Finding

All patients age 20 to 75 who are dyslipidemic and on a lipid-lowering medication

The preferred way to collect these data:

Patients 20 to 75 years old who are dyslipidemic and on a lipid-lowering medication could be identified. This would include patients with hypercholesterolemia (high low-density lipoprotein [LDL], normal triglycerides and high-density lipoprotein [HDL]), combined hyperlipidemia (high LDL and triglycerides), hypertriglyceridemia and hypercholesterolemia (with isolated low HDL) who are on a lipid-lowering medication.

Each medical group would select at random 20 patients for measurement each month to determine if a fasting lipid panel has been done in the past 3 to 12 months.

Data on 20 patients are collected monthly and reported quarterly.

### Denominator Sampling Frame

Patients associated with provider

### Denominator Inclusions/Exclusions

#### Inclusions

Total number of patients age 20 to 75 years old who are dyslipidemic and on lipid-lowering medication\* whose records are reviewed

\*Medications include: bile acid sequestrant (BAS), fibric acids, niacin, statins. Refer to Appendix C, "Drug Companion Document - Treatment Options for Dyslipidemia" in the original measure documentation for a complete listing of lipid-lowering medications.

#### Exclusions

Unspecified

### Relationship of Denominator to Numerator

All cases in the denominator are equally eligible to appear in the numerator

### Denominator (Index) Event

Clinical Condition

Therapeutic Intervention

## Denominator Time Window

Time window precedes index event

## Numerator Inclusions/Exclusions

### Inclusions

Number of patients on lipid-lowering medication who have had a fasting lipid panel\* in the past 3 to 12 months

\*Measurement of total cholesterol, high-density lipoprotein (HDL)-cholesterol, triglycerides and calculated low-density lipoprotein (LDL)-cholesterol after a 12-hour fasting period

### Exclusions

Unspecified

## Measure Results Under Control of Health Care Professionals, Organizations and/or Policymakers

The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.

## Numerator Time Window

Fixed time period

## Data Source

Administrative data

Medical record

## Level of Determination of Quality

Individual Case

## Pre-existing Instrument Used

Unspecified

## Computation of the Measure

## Scoring

Rate

## Interpretation of Score

Better quality is associated with a higher score

## Allowance for Patient Factors

Unspecified

## Standard of Comparison

Internal time comparison

## Evaluation of Measure Properties

### Extent of Measure Testing

Unspecified

## Identifying Information

### Original Title

Percentage of patients on a lipid-lowering medication who have a fasting lipid panel every 3 to 12 months.

### Measure Collection Name

Lipid Management in Adults Measures

### Submitter

Institute for Clinical Systems Improvement - Nonprofit Organization

### Developer

Institute for Clinical Systems Improvement - Nonprofit Organization

### Funding Source(s)

The following Minnesota health plans provide direct financial support: Blue Cross and Blue Shield of Minnesota, HealthPartners, Medica, Metropolitan Health Plan, PreferredOne, and UCare Minnesota. In-kind support is provided by the Institute for Clinical Systems Improvement's (ICSI) members.

### Composition of the Group that Developed the Measure

*Work Group Members:* Tony Woolley, MD (Work Group Leader) (Park Nicollet Health Services) (Internal Medicine); Stephen Kopecky, MD (Mayo Clinic) (Cardiology); Thomas Kottke, MD (HealthPartners Medical Group) (Cardiology); Patrick O'Connor, MD (HealthPartners Medical Group) (Family Medicine); Susan Hanson, RD (Park Nicollet Health Services) (Health Education); William Conroy, MD (Park Nicollet Health

Services) (Internal Medicine); Denise Dupras, MD (Mayo Clinic) (Internal Medicine); Phillip Kofron, MD, MPH (Park Nicollet Health Services) (Internal Medicine); Robert Needham, MD (Lakeview Clinic) (Internal Medicine); Deb J. Johnson, MSN (Marshfield Clinic) (Nursing); Mikel K. Bofenkamp, PharmD (Park Nicollet Health Services) (Pharmacy); Sarah Groen, PharmD (HealthPartners Medical Group) (Pharmacy); Kathy Cummings, RN, BSN, MA (Institute for Clinical Systems Improvement) (Facilitator); Linda Setterlund, MS, CPHQ (Institute for Clinical Systems Improvement) (Facilitator)

## Financial Disclosures/Other Potential Conflicts of Interest

The Institute for Clinical Systems Improvement (ICSI) has adopted a policy of transparency, disclosing potential conflict and competing interests of all individuals who participate in the development, revision and approval of ICSI documents (guidelines, order sets and protocols). This applies to all work groups (guidelines, order sets and protocols) and committees (Committee on Evidence-Based Practice, Cardiovascular Steering Committee, Women's Health Steering Committee, Preventive & Health Maintenance Steering Committee and Respiratory Steering Committee).

Participants must disclose any potential conflict and competing interests they or their dependents (spouse, dependent children, or others claimed as dependents) may have with any organization with commercial, proprietary, or political interests relevant to the topics covered by ICSI documents. Such disclosures will be shared with all individuals who prepare, review and approve ICSI documents.

Steven L. Kopecky MD is a consultant for Bayer, Fibrex, ParinGenix, Pinnacle Care, Prime Therapeutics and has received grant research support from AtherGenics, Integrium and Reliant.

Patrick J. O'Connor MD has received research funding from AHRQ, NHLBI, NIPPIS and NIA. All grant monies go to the HealthPartners Research Foundation. He also is a member of American Diabetes Association.

No work group members have potential conflicts of interest to disclose.

ICSI's conflict of interest policy and procedures are available for review on ICSI's website at [www.icsi.org](http://www.icsi.org) .

## Adaptation

Measure was not adapted from another source.

## Release Date

2003 Jul

## Revision Date

2009 Oct

## Measure Status

This is the current release of the measure.

This measure updates a previous version: Institute for Clinical Systems Improvement (ICSI). Lipid management in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2007 Jun. 77 p.

## Source(s)

Institute for Clinical Systems Improvement (ICSI). Lipid management in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2009 Oct. 72 p. [109 references]

## Measure Availability

The individual measure, "Percentage of Patients on a Lipid-lowering Medication Who Have a Fasting Lipid Panel Every 3 to 12 Months," is published in "Health Care Guideline: Lipid Management in Adults." This document is available from the [Institute for Clinical Systems Improvement \(ICSI\) Web site](#)

.

For more information, contact ICSI at, 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; phone: 952-814-7060; fax: 952-858-9675; Web site: [www.icsi.org](http://www.icsi.org) ; e-mail: [icsi.info@icsi.org](mailto:icsi.info@icsi.org).

## NQMC Status

This NQMC summary was completed by ECRI on April 28, 2004. This NQMC summary was updated by ECRI Institute on June 9, 2005, August 21, 2005, August 4, 2006, October 1, 2007, and again on June 9, 2010.

## Copyright Statement

This NQMC summary (abstracted Institute for Clinical Systems Improvement [ICSI] Measure) is based on the original measure, which is subject to the measure developer's copyright restrictions.

The abstracted ICSI Measures contained in this Web site may be downloaded by any individual or organization. If the abstracted ICSI Measures are downloaded by an individual, the individual may not distribute copies to third parties.

If the abstracted ICSI Measures are downloaded by an organization, copies may be distributed to the organization's employees but may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc.

All other copyright rights in the abstracted ICSI Measures are reserved by the Institute for Clinical Systems Improvement, Inc. The Institute for Clinical Systems Improvement, Inc. assumes no liability for any adaptations or revisions or modifications made to the abstracts of the ICSI Measures.

## Disclaimer

### NQMC Disclaimer

The National Quality Measures Clearinghouse (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the [NQMC Inclusion Criteria](#).

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its



reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes. Readers with questions regarding measure content are directed to contact the measure developer.